An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine
NCT00165880
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
62
Enrollment
INDUSTRY
Sponsor class
Stopped
This study was stopped prematurely due to lack of efficacy.
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
E7070
Sponsor
Eisai Limited